Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AN0025 + Pembrolizumab in Advanced Solid Tumors
NCT04432857Phase 1Active, not recruiting
- Sponsor
- Adlai Nortye
- Start
- Aug 2020
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of palupiprant in urothelial carcinoma (UC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and 2 more (6 arms), sponsored by Adlai Nortye. Primary endpoint: Dose-Limiting Toxicity at 3 weeks. Started Aug 2020; status: active, not recruiting.
02
Drugs
palupiprant
03
Conditions
urothelial carcinoma (UC)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)Cervical Cancer (CC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04432857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04432857.